Merck & Company Inc (MRK)vsStrata Critical Medical, Inc. (SRTA)
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
SRTA
Strata Critical Medical, Inc.
$5.77
-3.99%
HEALTHCARE · Cap: $392.79M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 26222% more annual revenue ($67.38B vs $255.97M). SRTA leads profitability with a 15.7% profit margin vs 3.6%. SRTA earns a higher WallStSmart Score of 51/100 (C-).
MRK
Hold44
out of 100
Grade: D
SRTA
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Intrinsic value data unavailable for SRTA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Revenue surging 60.7% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -9.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SRTA
The strongest argument for SRTA centers on Revenue Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.7% and operating margin at -6.3%. Revenue growth of 60.7% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : SRTA
The primary concerns for SRTA are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while SRTA is a growth play — different risk/reward profiles.
SRTA carries more volatility with a beta of 2.43 — expect wider price swings.
SRTA is growing revenue faster at 60.7% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
SRTA scores higher overall (51/100 vs 44/100), backed by strong 15.7% margins and 60.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Strata Critical Medical, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?